Data as of Q4 2025 (Dec 31, 2025)

venBio Partners LLC

โ€ขCIK: 1776382โ€ขFiling: Q4 2025

**venBio Partners LLC** manages $216M across a concentrated portfolio of six positions. The fund exhibits significant conviction in its top holding, allocating $128.7M to BLK, representing over 59% of reported assets. Further substantial allocations include $45.1M in ALMS and $18.3M in HRMY. This structure suggests a focused, high-conviction approach within its investment mandate.

Total AUM
$216.3M
QoQ Performance
+22.6%
Positions
6
Top 10 Concentration
100.0%
Latest Filing
Q4 2025

Top Holdings Allocation

PHAR
ALMS
HRMY
ALXO
PHARVARIS59.5%
ALMS20.8%
HRMY8.5%
ALXO5.1%
LYEL4.8%
ARTV1.3%

๐Ÿ“ˆ Biggest Buys

No new positions or increases this quarter

๐Ÿ“‰ Biggest Sells

LYEL
LYELL IMMUNOPHARMA INC
-28.7%
4.8% of portfolio
ARTV
ARTIVA BIOTHERAPEUTICS INC
-43.6%
1.3% of portfolio

Sector Breakdown

Other100.0%

Changes from Q3 2025

โ†“2 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023